A carregar...
PI3K Inhibitors: Present and Future
Inhibitors of PI3Kδ hold great potential for the therapy of CLL and B cell malignancies. After initially exciting efficacy results with idelalisib, the first in class inhibitor, the emergence of unexpected and unpredictable autoimmune toxicities, worse in less heavily treated and younger patients, h...
Na minha lista:
| Publicado no: | Cancer J |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7082729/ https://ncbi.nlm.nih.gov/pubmed/31764120 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000414 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|